SA
CTKB icon

Sanctuary Advisors’s Cytek Biosciences CTKB Stock Holding History

Sanctuary Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,225
Closed -$62K – 2440
2025
Q2 		$62K Buy
+18,225
New +$60.7K ﹤0.01% 2301

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanctuary Advisors's CTKB Position: Q3 2025 in Review

Sanctuary Advisors sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 18,225 shares — an estimated $62K sold.

Sanctuary Advisors first reported a position in CTKB in Q2 2025 and held it in 1 quarter. The position peaked at $62K in Q2 2025. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Sanctuary Advisors reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • Sanctuary Advisors sold 18,225 Cytek Biosciences shares in Q3 2025, an estimated $62K.
  • Sanctuary Advisors first reported a position in Cytek Biosciences in Q2 2025 and held it in 1 quarter.
  • Sanctuary Advisors's Cytek Biosciences position peaked at $62K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Sanctuary Advisors's 13F filing for Q3 2025, filed 6 Jan 2026.